drugset / Trial / NCT00667355

A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis

NCT00667355

Phase 3 Completed 41 enrolled Abbott Eisai Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with active ankylosing spondylitis

Timeline

Start
2008-02
Primary completion
2009-05
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject Adalimumab Monoclonal antibody 80 mg Subcutaneous